With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen

FDA approval of Crinetics Pharmaceuticals’ Palsonify makes it the first oral first-line therapy for acromegaly, a rare endocrine disorder. The once-daily pill will compete with blockbuster acromegaly drugs from Novartis and Ipsen that are administered as injections. The post With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen appeared…

Read More

Revenue cycle management checklist: improve experience & profits

As margins tighten, traditional revenue cycle management strategies are on shaky ground. Many healthcare providers are turning to automation and AI to simplify payments, prevent revenue loss and protect profits. This article breaks down some of the most common revenue cycle management (RCM) challenges facing healthcare leaders and offers a practical checklist to optimize patient…

Read More

We Should Write a Really Stern Letter

By KIM BELLARD On the heels of the disastrous floods in Texas, days away from the Hurricane Katrina twenty year anniversary, and with Hurricane Erin almost becoming another Hurricane Sandy, the dedicated employees at FEMA are worried. Very worried. They’ve got a President who repeatedly has called to dismantle the agency, a DHS Secretary who…

Read More

Journalists Recap State of NIH Cancer Research and Abortion Law’s Effect on Clinical Decisions

KFF Health News chief Washington correspondent Julie Rovner discussed Trump administration cuts to the National Institutes of Health on WNYC’s “The Brian Lehrer Show” on June 3. Click here to hear Rovner on “The Brian Lehrer Show.” KFF Health News Southern correspondent Sam Whitehead discussed Georgia’s abortion laws on WUGA’s “The Georgia Health Report” on May…

Read More